Protara Therapeutics, Inc. TARA
We take great care to ensure that the data presented and summarized in this overview for Protara Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TARA
View all-
Janus Henderson Group PLC London, X04.23MShares$23.3 Million0.01% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA2.14MShares$11.8 Million17.99% of portfolio
-
Blackstone Inc New York, NY1.91MShares$10.5 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.9MShares$10.5 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.75MShares$9.65 Million3.87% of portfolio
-
Catalio Capital Management, LP New York, NY1.5MShares$8.27 Million1.21% of portfolio
-
Integral Health Asset Management, LLC1.4MShares$7.71 Million0.46% of portfolio
-
Ubs Group Ag843KShares$4.65 Million0.0% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA800KShares$4.41 Million2.33% of portfolio
-
Geode Capital Management, LLC Boston, MA759KShares$4.18 Million0.0% of portfolio
Latest Institutional Activity in TARA
Top Purchases
Top Sells
About TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Insider Transactions at TARA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2025
|
Jesse Shefferman CEO and President |
SELL
Bona fide gift
|
Direct |
13,567
-0.7%
|
-
|
|
Jun 26
2025
|
Jesse Shefferman CEO and President |
SELL
Bona fide gift
|
Direct |
5,100
-0.26%
|
-
|
|
Jun 24
2025
|
Jesse Shefferman CEO and President |
SELL
Bona fide gift
|
Direct |
300,000
-31.25%
|
-
|
|
Jun 02
2025
|
William Conkling Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
May 14
2025
|
Richard S Levy |
BUY
Open market or private purchase
|
Direct |
20,000
+28.17%
|
$60,000
$3.19 P/Share
|
|
Apr 15
2025
|
Leonardo Viana Nicacio Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+48.93%
|
-
|
|
Mar 26
2025
|
Jacqueline Zummo Chf Scientific Operations Off |
SELL
Open market or private sale
|
Direct |
21,224
-17.67%
|
$84,896
$4.53 P/Share
|
|
Jan 24
2025
|
Patrick Fabbio Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+34.06%
|
-
|
|
Jan 24
2025
|
Hannah Fry VP, Controller |
BUY
Grant, award, or other acquisition
|
Direct |
9,500
+19.61%
|
-
|
|
Jan 24
2025
|
Jacqueline Zummo Chf Scientific Operations Off |
BUY
Grant, award, or other acquisition
|
Direct |
24,500
+16.21%
|
-
|
|
Jan 24
2025
|
Jesse Shefferman CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+6.14%
|
-
|
|
Jan 21
2025
|
Jacqueline Zummo Chf Scientific Operations Off |
SELL
Payment of exercise price or tax liability
|
Direct |
6,554
-6.42%
|
$26,216
$4.76 P/Share
|
|
Jan 21
2025
|
Hannah Fry VP, Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
2,130
-7.23%
|
$8,520
$4.76 P/Share
|
|
Jan 21
2025
|
Patrick Fabbio Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,061
-13.91%
|
$12,244
$4.76 P/Share
|
|
Jan 21
2025
|
Jesse Shefferman CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
15,469
-1.67%
|
$61,876
$4.76 P/Share
|
|
Jan 03
2025
|
Hannah Fry VP, Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
394
-1.32%
|
$2,364
$6.14 P/Share
|
|
Jan 03
2025
|
Jacqueline Zummo Chf Scientific Operations Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,157
-2.07%
|
$12,942
$6.14 P/Share
|
|
Jan 03
2025
|
Jesse Shefferman CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,479
-0.69%
|
$38,874
$6.14 P/Share
|
|
Sep 12
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
126,301
-9.21%
|
$126,301
$1.71 P/Share
|
|
Sep 11
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
32,600
-2.25%
|
$32,600
$1.71 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 20K shares |
|---|---|
| Grant, award, or other acquisition | 223K shares |
| Payment of exercise price or tax liability | 36.2K shares |
|---|---|
| Bona fide gift | 319K shares |
| Open market or private sale | 21.2K shares |